Luteolin induces apoptosis in azoxymethane-induced colon carcinogenesis through the involvement of Bcl-2, Bax and Caspase-3

Journal of Chemical and Pharmaceutical Research

Volumn 5, Issue 4, 2013, Pages 143-148

  Pandurangan, Ashok Kumar ^a   Ganapsam, Sudhandiran ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Apoptosis; Azoxymethane; Caspase 3; Luteolin

Indexed keywords

ANTI-INFLAMMATORIES; AZOXYMETHANE; CASPASE-3; CHEMOTHERAPEUTIC AGENTS; COLON CARCINOGENESIS; COLORECTAL CANCERS (CRC); LUTEOLIN; PREDICTABLE MECHANISMS;

CELL PROLIFERATION; DISEASES; ENZYMES; FLAVONOIDS;

CELL DEATH;

ACID PHOSPHATASE; AZOXYMETHANE; BETA GALACTOSIDASE; BETA GLUCURONIDASE; BETA N ACETYLGLUCURONIDASE; CASPASE 3; LUTEOLIN; LYSOSOME ENZYME; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

EID: 84877899687     PISSN: None     EISSN: 09757384     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. J Ferlay; HR Shin; F Bray; D Forman; C Mathers; DM Parkin, Int J Cancer, 2010, 127, 2893-917.
2. KM Mohandas, Indian J Gastroenterol., 2011, 30(1), 3-6.
3. TJ McDonnel, (1993). Mol. Carcinog., 1993, 8, 209-213.
4. DM Hockenbery; M Zutter; W Hicky; M Nahm; SJ Korsmeyer, Proc. Natl. Acad. Sci. USA., 1991, 88, 6961-6965.
5. H Zou; WJ Henzel; XS Liu; A Lutschg; XD Wang, Cell, 1997, 90, 405-13.
6. SM Srinivasula; M Ahmad; T Fernandes-Alnemri; ES Alnemri, Mol. Cell., 1998, 1, 949-57.
7. N Festjens; M van Gurp; G van Loo; X Saelens P Vandenabeele, Acta. Haematol., 2004, 111, 7-27.
8. P Greenwald; DW Nixon; WF Malone, et al, Cancer, 1990, 65, 1483-90.
9. WK Hong; MB Sporn, Science, 1997, 278, 1073-7.
10. LW Wattenberg, Cancer Res, 1983, 43, 2448S-53S.
11. LO Dragsted; M Strube, JC Larsen, Pharmacol Toxicol, 1993, 72, 116-35.
12. YJ Surh, Nature Rev, 2003, 3, 768-80.
13. JH Weisburger, Semin Oncol, 1991, 18, 316-36.
14. Y Nogata; K Sakamoto; H Shiratsuchi; et al, Biosci Biotech Bioch, 2006, 70, 178-92.
15. A Uehara; M Nakata; J Kitajima; et al, Biochem Syst Ecol, 2012, 41, 142-9.
16. N Sasaki; T Toda; T Kaneko; N Baba; M Matsuo, Chem. Biol. Int., 2003, 45(1), 101-16.
17. P Ashokkumar; G Sudhandiran, Biomed. Pharmacother., 2008, 62, 590-597.
18. P Ashokkumar; G Sudhandiran, Invest. New Drugs, 2011, 29(2), 273-84.
19. AK Pandurangan; P Dharmalingam; SK Anandasadagopan; S Ganapasam, Asian Pac. J. Cancer Prev., 2012,13(4), 1569-73.
20. AK Pandurangan; S Ganapasam, Asian Journal of Experimental Biological Sciences. 2013, (Accepted Manuscript).
21. Y Kawai; K Anno, Biochim. Biophys. Acta, 1971, 242, 428-436.
22. J Conchie; AL Gelman; GA Levvy, Biochem. J., 1967, 103, 609-615.
23. JC Moore; JE Morris, Ann. Clin. Biochem., 1982, 19, 157-159.
24. J King, Practical Clin. Enzymol., Nostrand Co, London, 1965, pp. 199-208.
25. N Sriram; S Kalayrasan; P Ashokkumar; A Sureshkumar; G Sudhandiran, Mol. Cell. Biochem., 2008, 311, 157-165.
26. MA Khandkar; DV Parmar, J. Pharm. Pharmacol. 1996, 48, 437-440.
27. AI Vengerovaski; AS Saratikov, Vopr. Med. Khim., 1989, 35, 87-91.
28. PH Whiting; PA Brown PA, Ren Fail., 1996, 18(6), 899-909.
29. CJ Olbricht; M Fink; E Gutjahr, Kidney Int., 1991, 39(4), 639-46.
30. AA Kyaw; T Aung; T Htut, Clin. Chim. Acta, 1983, 131, 317-23.
31. EC Dell'Angelica; C Mullins; S Caplan; JS Bonifacino, FASEB J., 2000, 14, 1265-78.
32. T Karrasch; JS Kim; BI Jang; C Jobin, Plos One., 2007, 7(596), 1-15.
33. M Horinaka; T Yoshida; T Shiraishi; S Nakata; M Wakada R Nakanishi; H Nishino H Matsui; T Sakai, Oncogene, 2005, 24, 7180-7189.
34. JFR Kerr; CM Winterford; BV Harmon, Cancer, 1994, 73, 2013-2026.
35. S Huerta; EJ Goulet; EH Livingston, Am. J. Surg., 2006, 191(4), 517-26.
36. A Bedi; PJ Pasricha; AJ Akhtar; JP Barber; GC Bedi; FM Giardiello; BA Zehnbauer; SR Hamilton; RJ Jones, Cancer Res. 1995, 55(9), 1811-6.
37. M Krajewska; SF Moss; S Krajewski K Song; PR Holt; JC Reed, Cancer Res., 1996, 56(10), 2422-2427.
38. HA Saleh; H Jackson; M Banerjee, Appl. Immunohistochem. Mol. Morphol., 2000, 8, 175-182.
39. C Yin; CM Knudson; SJ Korsmeyer; T Van Dyke, Nature, 1997, 385, 637-640.
40. T Fernándes-Alnemri; G Litwack; ES Alnmri, Cancer Res., 1995, 55, 2737-2742.
41. T Fernández-Alnemri; A Takahashi; R Armstrong; J Krebs; L Fritz; KJ Tomaselli; L Wang; Z Yu; CM Croce; G Salveson, Cancer Res. 1995a, 55, 6045-6055.
42. RA Gupta; RN DuBois, Nat. Rev. Cancer 2001, 1, 11-21.
43. C Wangchauy; S Chanprasert, J. Chem. Pharm. Res., 2012, 4(5), 2590-2598.
44. D S Samiulla; A Naidu; M Ramachandra, J. Chem. Pharm. Res., 2012, 4(6), 3129-3133.
45. S Sukjamnong; R Santiyanont, J. Chem. Pharm. Res., 2012, 4(5), 2483-2489
46. MR Haq; S Ashraf; CP Malik; AA Ganie; U Shandilya, J. Chem. Pharm. Res., 2011, 3(6), 601-608.
47. P Arulselvan; CC Wen; CW Lan; YH Chen; WC Wei; NS Yang, PLOS one, 2012, 7(9), e44658.
48. Y Ko; M Klinz; G Totzke; I Gouni-Berthold; A Sachinidis; H Vetter, Clin. Cancer Res., 1998, 4, 141-146.